Shanmughavel Piramanayagam

Dr. Shanmughavel Piramanayagam


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Genes & Diseases
Verified
Journal Article
Open access
SSSuganya Selvaraj
Suganya Selvaraj
SPShanmughavel Piramanayagam
Shanmughavel Piramanayagam
Parkinson's disease (PD) is the second most common age related neurodegenerative disorder worldwide and presents as a progressive movement disorder. Globally seven million to 10 million people have Parkinson's disease. Parkinsonism is typically sporadic in nature. Loss of dopaminergic neurons from substantia nigra pars compacta (SNpc) and the neuronal intracellular Lewy body inclusions are the major cause of PD. Gene mutation and protein aggregation play a pivotal role in the degeneration of dopamine neurons. But the actual cause of dopamine degeneration remains unknown. However, several rare familial forms of PD are associated with genetic loci, and the recognition of causal mutations has provided insight into the disease process. Yet, the molecular pathways and gene transformation that trigger neuronal susceptibility are inadequately comprehended. The discovery of a mutation in new genes has provided a basis for much of the ongoing molecular work in the PD field and testing of targeted therapeutics. Single gene mutation in a dominantly or recessively inherited gene results a great impact in the development of Parkinson's disease. In this review, we summarize the molecular genetics of PD.

30 August 2021 in Pharmacological Research
Verified
Journal Article
Closed access
LTLokesh Thangamani
Lokesh Thangamani
Balamuralikrishnan BalasubramanianBalamuralikrishnan Balasubramanian
Balamuralikrishnan Balasubramanian
MEMurugesh Easwaran
Murugesh Easwaran
JNJeyakumar Natarajan
Jeyakumar Natarajan
PKPushparaj Karthika
Pushparaj Karthika
SPShanmughavel Piramanayagam
Shanmughavel Piramanayagam

14 September 2015 in Journal of Molecular Modeling
Verified
Journal Article
Closed access
PDF file
SKSuhas Gorakh Karkute
Suhas Gorakh Karkute
MEMurugesh Easwaran
Murugesh Easwaran
Ranjit GujjarRanjit Gujjar
Ranjit Gujjar
SPShanmughavel Piramanayagam
Shanmughavel Piramanayagam
MSMajor Singh
Major Singh

25 April 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
YAYamuna Annadurai
Yamuna Annadurai
MEMurugesh Easwaran
Murugesh Easwaran
SSShobana Sundar
Shobana Sundar
LTLokesh Thangamani
Lokesh Thangamani
AMArun Meyyazhagan
Arun Meyyazhagan
SPShanmughavel Piramanayagam
Shanmughavel Piramanayagam
NIH reported 128 different types of cancer of which lung cancer is the leading cause of mortality. Globally, it is estimated that on average one in every seventeen hospitalized patients was deceased. There are plenty of studies that have been reported on lung cancer draggability and therapeutics, but yet a protein that plays a central specific to cure the disease remains unclear. So, this study is designed to identify the possible therapeutic targets and biomarkers that can be used for the potential treatment of lung cancers. In order to identify differentially expressed genes, 39 microarray datasets of lung cancer patients were obtained from various demographic regions of the GEO database available at NCBI. After annotating statistically, 6229 up-regulated genes and 10324 down-regulated genes were found. Out of 17 up-regulated genes and significant genes, we selected SPP1 (osteopontin) through virtual screening studies. We found functional interactions with the other cancer-associated genes such as VEGF, FGA, JUN, EGFR, and TGFB1. For the virtual screening studies,198 biological compounds were retrieved from the ACNPD database and docked with SPP1 protein (PDBID: 3DSF). In the results, two highly potential compounds secoisolariciresinol diglucoside (-12.9 kcal/mol), and Hesperidin (-12.0 kcal/mol) showed the highest binding affinity. The stability of the complex was accessed by 100 ns simulation in an SPC water model. From the functional insights obtained through these computational studies, we report that SPP1 could be a potential biomarker and successive therapeutic protein target for lung cancer treatment. Graphical Abstract Communicated by Ramaswamy H. Sarma


31 March 2021 in Bioinformation
Verified
Journal Article
Open access
PKPraveen Kumar Kumar
Praveen Kumar Kumar
SPShanmughavel Piramanayagam
Shanmughavel Piramanayagam
Antimicrobial peptides (AMPs) play a prominent role in drug discovery due to the rapid increase in drug resistant infections. Hence, we report the molecular docking analysis of antimicrobial peptides MREEKKERKRD and MVQGAKRGGRLHRV with the target protein CXCL1 in the context of colorectal cancer for further consideration in drug discovery.